XYMOGEN, INC.
ORLANDO, FLORIDA

magazine’s 5000 fastest-growing private companies for the tenth time, this past year has been both exciting and rewarding. This is a testament to the people, philosophy and culture that continue to make this journey we call XYMOGEN so exciting. We are committed long-term to all team members, customers and investors who have contributed and continue to contribute to our success What distinguishes XYMOGEN from other nutraceutical companies is our creativity. We are a very creative organization, and we strive to use our creativity in everything we do. I believe that the best way to predict the future is to create it, and our creativity helps us stay ahead of the competition and remain the premier source of nutritional products in the practitioner channel. As a result of our creative efforts, we have seen overwhelming success in our international expansion and also with our label publishing company, Labels in Motion™. We also plan to introduce numerous innovations in the coming year, including our ePedigree initiative and MedPax™, our science-based approach to personalized nutrition that allows practitioners and patients to create unique, daily supplement packets, designed to replace the patients’ many formula bottles, in addition to numerous other additions and revisions to enhance our formula line. On behalf of our ever growing XYMOGEN TEAM, I wish you all the best for a healthy, happy, and prosperous journey with us. Company Overview XYMOGEN® is a family-owned health sciences company headquartered in Orlando, Florida, that has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community, and its medical board of advisors consists of clinical practitioners who represent a broad range of specialties. XYMOGEN’s 136,000-square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International. The NSF mark assures consumers, retailers, and regulators that products have been rigorously tested to comply with all standard requirements. Since October 2015, XYMOGEN has had the unique distinction of being inspected and approved by Australia’s Therapeutic Goods Administration (TGA), the pharmaceutical regulatory agency of Australia. Considered the toughest regulatory agency in the world, the TGA inspection and certification is conducted at a pharmaceutical-level standard. Only a handful of U.S. companies are able to achieve the status of holding a TGA certification. XYMOGEN’s strength as a company has been reinforced for a tenth time, as it was recognized again in 2017 by Inc. magazine as one of the 5000 fastest-growing, best-run, most innovative and most inspiring private companies in America. With over 2,000 manufacturers in Central Florida, XYMOGEN was also the 2017 Manufacturers Association of Central Florida (MACF) recipient of the prestigious Award of Excellence for (large) Manufacturer of the Year. The award honored XYMOGEN for its distinction in strategic planning and leadership. XYMOGEN was also noted for its successful focus on its workforce, operations and customers. XYMOGEN is fortunate to be in the Practitioner Channel of the Health & Wellness Sector. Over the past five years, this has been among the fastest-growing business sectors in our country. At a time when few companies are growing, as of December 31, 2017, XYMOGEN has grown revenues for 55 consecutive quarters and has realized 120 percent growth in the past five years. Over this five-year period the share price has grown from $60.54 to $126.84. We believe with our current and planned initiatives the next five years will likely be our best growth period to date. XYMOGEN’s share price is valued quarterly, and, as of December 31, 2017, the share price is posted to our website with a value of $126.84. The next share valuation, as of March 31, 2018, will be posted to our website on or about April 15, 2018. In February 2010, XYMOGEN acquired Dr. David Perlmutter’s iNutritionals line of neurological formulas. The addition of BrainSustain™ and NeuroActives™ BrainSustain™ to the XYMOGEN line positions us as a leader in the modulation of neurological disorders. XYMOGEN's continued growth and success allows us to keep expanding and improving our line of formulas in order to meet patients’ health needs. Our quarterly releases of innovative formulas reflect the latest scientific findings in the field of nutritional science as well as feedback from our Medical Board of Advisors and XYMOGEN practitioners worldwide. XYMOGEN continues to see new opportunities to address the ever-expanding need for natural health solutions by distributing its top-of-the-line formulas across the global market. The goal is to ensure XYMOGEN products are supplied to every distributor that recognizes the benefits of providing these innovative formulas to consumers, and has a desire to help people achieve a healthier lifestyle. XYMOGEN is currently distributing in Canada (where XYMOGEN maintains its own sales force and fulfillment center), South Korea, South Africa, China, Taiwan, Singapore, Australia, New Zealand, Mexico, Indonesia, Peru, Ecuador, Vietnam, and Ukraine – and is looking to develop markets in Iran, Saudi Arabia, Pakistan and throughout Europe. These future ventures can only be realized through strong partnerships with potential distributors who share XYMOGEN’s vision. XYMOGEN provides products only to licensed healthcare practitioners and their authorized patients. Products sold through discount Internet websites are strictly prohibited. These suppliers are not approved distributors, and XYMOGEN cannot guarantee the authenticity, potency or efficacy of products purchased through such sites. The main goal of our ePedigree initiative is to protect consumers from receiving unauthentic XYMOGEN products from unauthorized Internet sources by creating an electronic record which tracks our products as they move from the manufacturing floor to the customer. With ePedigree, we are eliminating all Internet sales of XYMOGEN-labeled formulas, resulting in XYMOGEN being the only truly exclusive source of proprietary supplements in the practitioner channel.